X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Natco Pharma with SUVEN LIFE - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NATCO PHARMA vs SUVEN LIFE - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NATCO PHARMA SUVEN LIFE NATCO PHARMA/
SUVEN LIFE
 
P/E (TTM) x 30.7 20.1 152.9% View Chart
P/BV x 23.2 3.7 624.4% View Chart
Dividend Yield % 0.5 1.0 48.9%  

Financials

 NATCO PHARMA   SUVEN LIFE
EQUITY SHARE DATA
    NATCO PHARMA
Mar-14
SUVEN LIFE
Mar-16
NATCO PHARMA/
SUVEN LIFE
5-Yr Chart
Click to enlarge
High Rs877339 259.1%   
Low Rs424144 293.3%   
Sales per share (Unadj.) Rs223.439.2 569.3%  
Earnings per share (Unadj.) Rs31.17.5 416.4%  
Cash flow per share (Unadj.) Rs40.38.8 458.9%  
Dividends per share (Unadj.) Rs5.002.00 250.0%  
Dividend yield (eoy) %0.80.8 92.8%  
Book value per share (Unadj.) Rs219.549.0 448.0%  
Shares outstanding (eoy) m33.07127.28 26.0%   
Bonus/Rights/Conversions PA--  
Price / Sales ratio x2.96.2 47.3%   
Avg P/E ratio x20.932.4 64.7%  
P/CF ratio (eoy) x16.127.5 58.7%  
Price / Book Value ratio x3.04.9 60.1%  
Dividend payout %16.126.8 60.0%   
Avg Mkt Cap Rs m21,50430,732 70.0%   
No. of employees `000NA1.0 0.0%   
Total wages/salary Rs m1,128416 270.8%   
Avg. sales/employee Rs ThNM5,236.1-  
Avg. wages/employee Rs ThNM436.5-  
Avg. net profit/employee Rs ThNM995.5-  
INCOME DATA
Net Sales Rs m7,3894,995 147.9%  
Other income Rs m167194 86.4%   
Total revenues Rs m7,5565,189 145.6%   
Gross profit Rs m1,7931,233 145.5%  
Depreciation Rs m304167 182.1%   
Interest Rs m36654 675.6%   
Profit before tax Rs m1,2901,205 107.1%   
Minority Interest Rs m460-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m309255 121.1%   
Profit after tax Rs m1,027950 108.2%  
Gross profit margin %24.324.7 98.4%  
Effective tax rate %23.921.2 113.1%   
Net profit margin %13.919.0 73.1%  
BALANCE SHEET DATA
Current assets Rs m3,6814,986 73.8%   
Current liabilities Rs m3,1231,042 299.6%   
Net working cap to sales %7.679.0 9.6%  
Current ratio x1.24.8 24.6%  
Inventory Days Days8961 146.7%  
Debtors Days Days5939 150.0%  
Net fixed assets Rs m7,6853,126 245.9%   
Share capital Rs m331127 259.8%   
"Free" reserves Rs m6,6703,717 179.4%   
Net worth Rs m7,2596,236 116.4%   
Long term debt Rs m955432 220.9%   
Total assets Rs m11,9578,079 148.0%  
Interest coverage x4.523.2 19.5%   
Debt to equity ratio x0.10.1 189.8%  
Sales to assets ratio x0.60.6 99.9%   
Return on assets %11.712.4 93.8%  
Return on equity %14.215.2 92.9%  
Return on capital %20.718.9 109.8%  
Exports to sales %39.487.5 45.0%   
Imports to sales %5.712.2 46.6%   
Exports (fob) Rs m2,9084,371 66.5%   
Imports (cif) Rs m421611 69.0%   
Fx inflow Rs m3,4454,666 73.8%   
Fx outflow Rs m703942 74.6%   
Net fx Rs m2,7433,724 73.6%   
CASH FLOW
From Operations Rs m1,440922 156.2%  
From Investments Rs m-1,089-619 175.9%  
From Financial Activity Rs m-353-698 50.5%  
Net Cashflow Rs m-1-396 0.4%  

Share Holding

Indian Promoters % 52.0 63.4 82.1%  
Foreign collaborators % 1.5 0.0 -  
Indian inst/Mut Fund % 7.8 0.0 -  
FIIs % 16.6 0.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 26.0 36.5 71.2%  
Shareholders   25,395 37,287 68.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NATCO PHARMA With:   J.B.CHEMICALS  VENUS REMEDIES  STERLING BIOTECH  CADILA HEALTHCARE  ALEMBIC LTD  

Compare NATCO PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Of Global Markets Hitting Record Highs and Top Stocks in Action During the Week(RoundUp)

Global stock markets ended the week on a positive note. Benchmark indices in US grew by 1% during the week. The Down Jones Industrial Average topped the 26,000.

Related Views on News

Suven Lifesciences: Profits Decline due to Higher tax outgo in the quarter (Quarterly Results Update - Detailed)

Sep 22, 2017

Muted growth in CRAMS segment continues to impact topline.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NATCO PHARMA SHARE PRICE


Jan 19, 2018 (Close)

TRACK NATCO PHARMA

  • Track your investment in NATCO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NATCO PHARMA - UNICHEM LAB COMPARISON

COMPARE NATCO PHARMA WITH

MARKET STATS